Vanguard Group
SPRY icon

Vanguard Group’s ARS Pharmaceuticals SPRY Stock Holding History

Vanguard Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40.9M Buy
3,509,174
+8,871
+0.3% +$86.3K ﹤0.01% 2277
2025
Q3 		$35.2M Buy
3,500,303
+237,630
+7% +$3.41M ﹤0.01% 2327
2025
Q2 		$56.9M Sell
3,262,673
-225,620
-6% -$3.26M ﹤0.01% 2067
2025
Q1 		$43.9M Buy
3,488,293
+23,341
+0.7% +$281K ﹤0.01% 2145
2024
Q4 		$36.6M Buy
3,464,952
+115,656
+3% +$1.62M ﹤0.01% 2294
2024
Q3 		$48.6M Buy
3,349,296
+98,369
+3% +$1.17M ﹤0.01% 2190
2024
Q2 		$27.7M Buy
3,250,927
+364,472
+13% +$3.23M ﹤0.01% 2403
2024
Q1 		$29.5M Buy
2,886,455
+779,969
+37% +$5.82M ﹤0.01% 2407
2023
Q4 		$11.5M Sell
2,106,486
-14,803
-0.7% -$64.9K ﹤0.01% 2865
2023
Q3 		$8.02M Buy
2,121,289
+276,097
+15% +$1.81M ﹤0.01% 3009
2023
Q2 		$12.4M Buy
1,845,192
+147,555
+9% +$985K ﹤0.01% 2824
2023
Q1 		$11.1M Buy
1,697,637
+9,717
+0.6% +$74.7K ﹤0.01% 2883
2022
Q4 		$14.4M Buy
1,687,920
+600,749
+55% +$3.9M ﹤0.01% 2792
2022
Q3 		$5.74M Buy
1,087,171
+30,507
+3% +$150K ﹤0.01% 3248
2022
Q2 		$4.48M Buy
1,056,664
+233,368
+28% +$814K ﹤0.01% 3428
2022
Q1 		$2.89M Sell
823,296
-488,370
-37% -$2.13M ﹤0.01% 3793
2021
Q4 		$8.73M Sell
1,311,666
-357,428
-21% -$2.9M ﹤0.01% 3293
2021
Q3 		$16.7M Buy
1,669,094
+673,544
+68% +$16.6M ﹤0.01% 2960
2021
Q2 		$30.8M Sell
995,550
-89,942
-8% -$2.88M ﹤0.01% 2618
2021
Q1 		$47.4M Buy
1,085,492
+1,035,492
+2,071% +$49M ﹤0.01% 2345
2020
Q4 		$2.32M Buy
+50,000
New +$1.67M ﹤0.01% 3626

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group's SPRY Position: Q4 2025 in Review

Vanguard Group increased its ARS Pharmaceuticals (SPRY) stake by 0.25% in Q4 2025, buying an estimated $86.3K and bringing the position to 3,509,174 shares worth $40.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Vanguard Group first reported a position in SPRY in Q4 2020 and has held it in 21 quarters since. The position peaked at $56.9M in Q2 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Vanguard Group held 3,509,174 shares of ARS Pharmaceuticals worth $40.9M as of Q4 2025.
  • Vanguard Group bought 8,871 ARS Pharmaceuticals shares in Q4 2025, an estimated $86.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2277 holding.
  • Vanguard Group first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Vanguard Group's ARS Pharmaceuticals position peaked at $56.9M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.